Introduction

In a case that closed as quietly as it began, Azurity Pharmaceuticals, Inc. v. Cosette Pharmaceuticals, Inc. (Case No. 2:23-cv-03830) concluded with a stipulated dismissal without prejudice after just 244 days in the District of New Jersey. Filed on July 18, 2023, and resolved by March 18, 2024, the dispute centered on U.S. Patent No. 11,638,692 B2 — covering a composition and method for vancomycin oral liquid formulations.

While the case produced no courtroom verdict, its resolution carries meaningful signals for pharmaceutical patent practitioners. Stipulated dismissals in pharmaceutical infringement actions often reflect confidential licensing agreements, commercial recalibrations, or strategic retreats — each carrying distinct implications for competitive positioning in the specialty drug formulation space.

For patent attorneys tracking ANDA-adjacent litigation, in-house IP counsel at pharmaceutical companies, and R&D teams navigating formulation patents, this case offers a concise but instructive window into how vancomycin oral liquid patent infringement disputes are being managed at the district court level.

Case Overview

The Parties

The Patent at Issue

This case involved U.S. Patent No. 11,638,692 B2, which covers a composition and method for vancomycin oral liquid formulations. Vancomycin is a critical antibiotic, and oral liquid formulations expand patient access, particularly for pediatric and elderly populations.

• • US 11,638,692 B2 — Composition and method for vancomycin oral liquid

The Accused Product

Cosette’s accused product involved a vancomycin oral liquid composition — a direct competitive alternative to Azurity’s patented formulation. The commercial stakes are meaningful: oral vancomycin formulations serve patients who cannot use capsules, and branded liquid formulations command significant price premiums over compounded or generic alternatives.

Legal Representation

Plaintiff (Azurity): Arnold B. Calmann and Katherine Ann Escanlar of Saiber LLC.
Defendant (Cosette): Nicole Gerritsen McDonough of Sills Cummis & Gross PC.

Litigation Timeline & Procedural History

Azurity filed suit in the District of New Jersey — a deliberate and strategically sound venue choice. New Jersey hosts a dense concentration of pharmaceutical patent litigation, given the state’s role as a hub for major drug manufacturers. District of New Jersey judges carry deep familiarity with Hatch-Waxman litigation frameworks and pharmaceutical patent disputes, making it a predictable forum for pharmaceutical plaintiffs.

The case resolved at the first-instance trial level without proceeding to claim construction, summary judgment, or trial. At 244 days — under eight months — the matter closed relatively quickly by pharmaceutical patent litigation standards, where disputes routinely extend two to four years. No chief judge assignment data was disclosed in the case record.

The swift resolution strongly suggests the parties reached an early understanding, whether through licensing, market accommodation, or a decision by one party to withdraw from the contested product space pending further patent prosecution or portfolio assessment.

The Verdict & Legal Analysis

Outcome

The case concluded via Stipulation and Order of Dismissal pursuant to Federal Rule of Civil Procedure 41(a)(2). Key terms of the dismissal include:

• • All claims and counterclaims dismissed without prejudice
• • Each party bears its own attorneys’ fees and costs
• • No damages were awarded; no injunctive relief was entered

The “without prejudice” designation is particularly significant. It preserves Azurity’s right to refile infringement claims against Cosette if circumstances change — for example, if Cosette relaunches an accused product, modifies its formulation, or if Azurity secures additional patents in the vancomycin oral liquid space.

Verdict Cause Analysis

The underlying cause of action was a straightforward patent infringement action — Azurity alleged that Cosette’s vancomycin oral liquid product infringed the claims of U.S. Patent No. 11,638,692 B2. Because the case dismissed before substantive merits rulings, no formal findings were made regarding:

• • Claim construction of the ‘692 patent
• • Validity of the asserted claims (no obviousness or enablement rulings)
• • Infringement findings (literal or under the doctrine of equivalents)
• • Damages quantum or methodology

The absence of these rulings means the patent’s legal strength — and Cosette’s infringement exposure — remains publicly unresolved. This ambiguity is itself strategically valuable to both parties: Azurity retains an unadjudicated patent with no adverse validity findings, while Cosette avoids a precedent-setting infringement determination.

Legal Significance

From a precedential standpoint, this dismissal without prejudice produces no binding legal authority. However, it contributes to the broader pattern of pharmaceutical patent disputes resolving through negotiated resolution rather than adjudication — a trend with meaningful implications for how formulation patents are enforced and challenged in this sector.

The use of Rule 41(a)(2) dismissal — requiring court approval — rather than a Rule 41(a)(1) stipulation suggests a degree of procedural formality, potentially reflecting court-mediated resolution or structured settlement terms not publicly disclosed.

Strategic Takeaways

For Patent Holders: Filing in the District of New Jersey for pharmaceutical formulation patents remains strategically sound. Even where cases resolve early, the filing itself — particularly under a strong patent number — signals enforcement intent to the market. The “without prejudice” dismissal preserves Azurity’s legal options while potentially having achieved commercial objectives through non-public terms.

For Accused Infringers: Early resolution avoiding claim construction and validity rulings prevents adverse precedent. Cosette’s decision to litigate through Sills Cummis & Gross rather than immediately settling suggests meaningful initial resistance, ultimately resolved through negotiation. Design-around analysis of the ‘692 patent claims remains a viable path for any future vancomycin oral liquid product development.

For R&D Teams: U.S. Patent No. 11,638,692 B2 remains an active, unchallenged patent with no adverse validity rulings. Any developer working in vancomycin oral liquid formulations should conduct a Freedom to Operate (FTO) analysis relative to this patent — particularly since dismissal without prejudice signals the patent holder’s willingness to enforce and potentially refile.

Industry & Competitive Implications

The vancomycin oral liquid segment is a niche but defensible market. Branded formulations supported by composition-and-method patents create meaningful barriers for generic entrants, even absent FDA exclusivity protections. Azurity’s enforcement posture — filing suit promptly after alleged infringement — signals a strategy of active patent monetization in specialty liquid formulations.

For Cosette and similarly positioned generic manufacturers, this case illustrates the resource and time costs of entering patent-protected formulation markets without pre-litigation FTO clearance or a clear design-around strategy. The mutual fee-bearing structure of the dismissal means both parties absorbed their own litigation costs — an outcome that neither side can claim as a clear financial victory.

More broadly, this case reflects an industry trend: pharmaceutical patent disputes increasingly resolve through confidential agreements before any substantive judicial merits determination. This creates information asymmetry — competitors and market watchers cannot assess patent strength from public rulings — making robust pre-market patent landscape analysis even more critical.

Licensing in the specialty pharma formulation space continues to be preferred over protracted litigation, particularly for second-tier market entrants where litigation costs can outweigh market opportunity.